Requirements for clinical PET: Comparisons within Europe

被引:29
作者
Bedford, M [1 ]
Maisey, MN [1 ]
机构
[1] Guys Hosp, London SE1 9RT, England
关键词
positron emission tomography; cancer; modelling; costs; healthcare;
D O I
10.1007/s00259-003-1351-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim was to assess the requirements for a positron emission tomography (PET) cancer imaging service. The UK was used as an example to create a mathematical model for calculating the number of dedicated PET scanners and cyclotron/radiochemistry production facilities required to support the demand for PET studies in lung cancer. This was then extended to all oncological indications for PET and comparison was made with present infrastructure in the UK and Europe. A clinical algorithm for the use of PET in lung cancer management was created and built into a comprehensive computer model with variable parameters. From lung cancer incidences, data reported in the literature and local data, the proportion of patients following each algorithmic path was determined and used to calculate the number of PET scans and hence PET scanners required for lung cancer, and all cancer indications. Substituting lung cancer incidences, the PET infrastructure required for each European country was assessed. From this analysis, 29,886 PET scans per year for lung cancer investigation (provision of 12 scanners) and 121,589 PET scans (2,026.5 per million population) for all indications [provision of 49 scanners (0.82 per million population)] are required in the UK; at present there are seven scanners, and thus 42 new scanners are required. Results reported here demonstrate considerable lack of investment in PET in Europe, with marked variation; Belgium has the most sufficient infrastructure (197.80% of requirements), and excluding France, which is soon to see extensive development, the UK has the least sufficient infrastructure (14.39% of requirements). Considerable investment is required so that cancer management can gain the clinical and cost-effective benefit of this functional imaging technique, which has been established.
引用
收藏
页码:208 / 221
页数:14
相关论文
共 98 条
[61]   THORACIC NODAL STAGING WITH PET IMAGING WITH (18)FDG IN PATIENTS WITH BRONCHOGENIC-CARCINOMA [J].
PATZ, EF ;
LOWE, VJ ;
GOODMAN, PC ;
HERNDON, J .
CHEST, 1995, 108 (06) :1617-1621
[62]   PERSISTENT OR RECURRENT BRONCHOGENIC-CARCINOMA - DETECTION WITH PET AND 2-[F-18]-2-DEOXY-D-GLUCOSE [J].
PATZ, EF ;
LOWE, VJ ;
HOFFMAN, JM ;
PAINE, SS ;
HARRIS, LK ;
GOODMAN, PC .
RADIOLOGY, 1994, 191 (02) :379-382
[63]  
PAUKER SG, 1992, MED USES STAT, P159
[64]   Preoperative staging of non-small-cell lung cancer with positron-emission tomography. [J].
Pieterman, RM ;
van Putten, JWG ;
Meuzelaar, JJ ;
Mooyaart, EL ;
Vaalburg, W ;
Koëter, GH ;
Fidler, V ;
Pruim, J ;
Groen, HJM .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (04) :254-261
[65]   PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma [J].
Poncelet, AJ ;
Lonneux, M ;
Coche, E ;
Weynand, B ;
Noirhomme, P ;
Collard, P ;
Humblet, Y ;
Liistro, G ;
Pieters, T ;
Rodenstein, D ;
Scaillet, P .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2001, 20 (03) :468-474
[66]   BRONCHOGENIC-CARCINOMA - UTILITY OF CT IN THE EVALUATION OF PATIENTS WITH SUSPECTED LESIONS [J].
PRIMACK, SL ;
LEE, KS ;
LOGAN, PM ;
MILLER, RR ;
MULLER, NL .
RADIOLOGY, 1994, 193 (03) :795-800
[67]  
QUINN M, 2001, NATL STAT PUBLICATIO, P84
[68]  
QUINN M, 2000, HLTH STAT Q 0807
[69]  
Royal College of Physicians of London, 2003, POS EM TOM STRAT PRO
[70]   Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer [J].
Sazon, DAD ;
Santiago, SM ;
Hoo, GWS ;
Khonsary, A ;
Brown, C ;
Mandelkern, M ;
Blahd, W ;
Williams, AJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (01) :417-421